

S3 Table. Subgroup analyses of associations between fatty liver diseases and hepatocellular carcinoma risk among individuals without one chronic liver condition

Disease	Absence of chronic liver disease (n=27,545)			Absence of chronic viral hepatitis (n=25,989)			Absence of cirrhosis (n=27,628)		
	No. cases	Incidence (per 100,000 person-years)	Adjusted HR (95% CI)	No. cases	Incidence (per 100,000 person-years)	Adjusted HR (95% CI)	No. cases	Incidence (per 100,000 person-years)	Adjusted HR (95% CI)
Fatty liver disease									
Absence	66	25.93	1.00 (reference)	23	9.56	1.00 (reference)	57	22.32	1.00 (reference)
Presence	47	32.68	1.79 (1.17-2.75) ^{a)}	27	19.72	2.03 (1.12-3.69) ^{a)}	51	35.37	1.57 (1.06-2.31) ^{a)}
NAFLD									
Absence	97	31.15	1.00 (reference)	34	11.69	1.00 (reference)	92	29.42	1.00 (reference)
Presence	12	14.93	1.41 (0.71-2.79)	12	14.93	1.47 (0.74-2.91)	12	14.93	1.31 (0.67-2.56)
MAFLD									
Absence	70	26.27	1.00 (reference)	24	9.53	1.00 (reference)	61	22.81	1.00 (reference)
Presence	43	32.69	1.74 (1.14-2.65) ^{a)}	26	20.75	2.11 (1.17-3.80) ^{a)}	47	35.64	1.53 (1.03-2.25) ^{a)}
MASLD									
Absence	97	31.02	1.00 (reference)	32	10.96	1.00 (reference)	90	28.68	1.00 (reference)
Presence	12	15.87	1.49 (0.75-2.94)	13	17.13	1.67 (0.86-3.24)	13	17.16	1.57 (0.81-3.03)
MetALD									
Absence	104	27.47	1.00 (reference)	44	12.26	1.00 (reference)	96	25.27	1.00 (reference)
Presence	3	23.05	0.97 (0.30-3.09)	1	8.15	0.55 (0.08-4.04)	5	38.33	1.41 (0.57-3.49)
ALD									
Absence	105	27.69	1.00 (reference)	43	11.97	1.00 (reference)	99	26.03	1.00 (reference)
Presence	2	15.58	0.70 (0.17-2.87)	2	16.38	1.20 (0.29-5.01)	2	15.55	0.60 (0.15-2.43)

Multivariable models were adjusted for age, sex, chronic liver disease (where applicable), chronic viral hepatitis (where applicable), cirrhosis (where applicable), and fibrosis-4. ALD, alcohol-related liver disease; CI, confidence interval; HR, hazard ratio; MAFLD, metabolic dysfunction–associated fatty liver disease; MASLD, metabolic dysfunction–associated steatotic liver disease; MetALD, metabolic dysfunction–associated steatotic liver disease with increased alcohol intake; NAFLD, nonalcoholic fatty liver disease.

^{a)}Significant differences.